Preclinical
Eliem Therapeutics could be in trouble following the announcement that its drug candidate ETX-810, intended to treat diabetic peripheral neuropathic pain, did not meet its primary endpoint.
Sionna hit the ground with a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in CF patients.
Heat Biologics announced a new development underway in its partnership with Scorpion Biological Services to develop a manufacturing facility in Manhattan, Kansas.
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.
Companies working on cell therapies got most of the funding in the life sciences venture capital world this week. For that and more, continue reading.
“I want to put together cures for AstraZeneca and patients,” Matthew Ellis, the company’s new SVP of early oncology told BioSpace in an interview.
EXUMA Biotech is developing a new modality to produce CAR cells in a single day, with potentially lower toxicity and higher efficacy without the need for preparative chemotherapies.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading.
Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on Monday and recapped the laundry list of vaccines and treatments the company plans to develop.
PRESS RELEASES